INmune Bio (NASDAQ:INMB - Get Free Report) is projected to announce its Q1 2025 earnings results before the market opens on Thursday, May 8th. Analysts expect INmune Bio to post earnings of ($0.43) per share for the quarter.
INmune Bio (NASDAQ:INMB - Get Free Report) last posted its earnings results on Thursday, March 27th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.14. On average, analysts expect INmune Bio to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
INmune Bio Stock Performance
Shares of INmune Bio stock traded up $0.17 during trading hours on Friday, hitting $7.76. The company's stock had a trading volume of 224,791 shares, compared to its average volume of 252,200. The stock has a market cap of $178.36 million, a price-to-earnings ratio of -3.56 and a beta of 1.86. INmune Bio has a twelve month low of $4.32 and a twelve month high of $11.76. The firm has a fifty day moving average of $7.76 and a 200-day moving average of $6.79.
Wall Street Analyst Weigh In
Several research analysts have weighed in on INMB shares. Maxim Group increased their target price on shares of INmune Bio from $22.00 to $30.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th. RODMAN&RENSHAW raised shares of INmune Bio to a "strong-buy" rating in a research report on Tuesday, January 28th. Scotiabank boosted their target price on INmune Bio from $22.00 to $23.00 and gave the company a "sector outperform" rating in a research report on Tuesday, February 11th. Finally, Rodman & Renshaw assumed coverage on INmune Bio in a research report on Tuesday, January 28th. They set a "buy" rating and a $23.00 price target for the company. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, INmune Bio currently has an average rating of "Buy" and a consensus target price of $22.80.
Get Our Latest Research Report on INMB
INmune Bio Company Profile
(
Get Free Report)
INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Recommended Stories
Before you consider INmune Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and INmune Bio wasn't on the list.
While INmune Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
